<DOC>
	<DOC>NCT00034892</DOC>
	<brief_summary>The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day) in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder who are experiencing their first psychotic episode.</brief_summary>
	<brief_title>CAFE Comparison of Atypicals in First Episode of Psychosis</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Patients must meet criteria for schizophreniform disorder, schizophrenia, or schizoaffective disorder with psychotic symptoms lasting 160 months Psychotic symptoms must have persisted at least one month, and not more thn 5 years (60 months) Patients must have no previous history of drug treatment (greater than a total of 16 weeks) with antipsychotics Patients with history of psychotic disorder with recovery period of at least 3 months Female patients who are pregnant or nursing Patients with a known history of mental retardation</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>